We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Proton Therapy Has Better Outcome over IMRT for Advanced Head and Neck Cancers

By MedImaging International staff writers
Posted on 21 Jul 2014
Print article
Radiation oncologists compared the world’s literature on outcomes of proton beam therapy in the treatment of a range of advanced head and neck cancers of the skull base compared to intensity-modulated radiation therapy (IMRT) and found that proton beam therapy significantly improved disease-free survival and tumor control when compared to IMRT.

The study’s findings were published June 27, 2014, in the journal Lancet Oncology. “We undertook a systematic review and meta-analysis to compare the clinical outcomes of patients treated with proton therapy with patients receiving photon IMRT,” said senior author Robert Foote, MD, a radiation oncologist at the Mayo Clinic (Rochester, MN, USA). “Our findings suggest that the theoretical advantages of proton beam therapy may in fact be real.”

Researchers reviewed cases of nasal cavity and paranasal sinus tumors through extensive database searches. They included studies of patients who had no earlier treatment—neither primary radiation therapy nor adjuvant radiation therapy—and patients who had recurrent disease. Researchers collected data on overall survival, disease-free survival, and tumor control, at five years and at the patient’s longest follow-up. They used random-effect models to pool outcomes across studies and compared event rates of combined outcomes for proton therapy and IMRT using an interaction test.

Researchers discovered disease-free survival to be significantly higher at five years for patients receiving proton therapy than for patients receiving IMRT (72% versus 50%). Tumor control did not differ between treatment groups at five years however tumor control was higher for patients receiving proton therapy than for IMRT at the longest follow-up (81% versus 64%).


Related Links:

Mayo Clinic


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Digital Radiography Acquisition Software
VXvue with PureImpact
Gold Member
Radiation QA Tool
Accu-Gold 3
New
Thyroid Shield
Standard Thyroid Shield

Print article

Channels

Ultrasound

view channel
Image: Structure of the proposed transparent ultrasound transducer and its optical transmittance (Photo courtesy of POSTECH)

Ultrasensitive Broadband Transparent Ultrasound Transducer Enhances Medical Diagnosis

The ultrasound-photoacoustic dual-modal imaging system combines molecular imaging contrast with ultrasound imaging. It can display molecular and structural details inside the body in real time without... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: The acquisition will expand IBA’s medical imaging quality assurance offering (Photo courtesy of Radcal)

IBA Acquires Radcal to Expand Medical Imaging Quality Assurance Offering

Ion Beam Applications S.A. (IBA, Louvain-La-Neuve, Belgium), the global leader in particle accelerator technology and a world-leading provider of dosimetry and quality assurance (QA) solutions, has entered... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.